2017

Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis

May-Wilson S

Elsevier BV

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
© Authors
CC BY http://creativecommons.org/licenses/by/4.0/
http://dx.doi.org/10.1016/j.ejca.2017.07.034

https://erepo.uef.fi/handle/123456789/5167

Downloaded from University of Eastern Finland's eRepository
Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis

Sebastian May-Wilson a,1, Amit Sud a,1, Philip J. Law a,1, Kimmo Palin b,c, Sari Tuupanen b,c, Alexandra Gylfe b,c, Ulrika A. Hänninen b,c, Tatiana Cajuso b,c, Tomas Tanskanen b,c, Johanna Kondelin b,c, Eevi Kaasinen b,c, Anti-Pekka Sarin d, Johan G. Eriksson g,h,i, Harri Rissanen g, Paul Knekt g, Eero Pukkala j,k, Pekka Jousilahti g, Veikko Salomaa g, Samuli Ripatti d,e,f, Aarno Palotie d,l,m,n, Laura Renkonen-Sinisalo o, Anna Lepistö o, Jan Böhm p, Jukka-Pekka Mecklin q, Nada A. Al-Tassan r, Claire Palles s, Susan M. Farrington t, Maria N. Timofeeva t, Brian F. Meyer r, Salma M. Wakil t, Harry Campbell u, Christopher G. Smith v, Shelley Idziasczyk v, Timothy S. Maughan w, David Fisher x, Rachel Kerr y, David Kerr z, Michael N. Passarelli aa, Jane C. Figueiredo ab,ac, Daniel D. Buchanan ad,ae, Aung K. Win ae, John L. Hopper ae, Mark A. Jenkins ae, Noralane M. Lindor af, Polly A. Newcomb ag, Steven Gallinger ah, David Conti ai, Fred Schumacher aj, Graham Casey aj, Lauri A. Aaltonen b,c, Jeremy P. Cheadle v, Ian P. Tomlinson s, Malcolm G. Dunlop t, Richard S. Houlston a,*

* Corresponding author: Division of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, London, SM2 5NG, UK.
Fax: +44 (0) 722 4365.
E-mail address: richard.houlston@icr.ac.uk (R.S. Houlston).

1 These authors contributed equally to this work.

http://dx.doi.org/10.1016/j.ejca.2017.07.034
0959-8049/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Abstract  Background: While dietary fat has been established as a risk factor for colorectal cancer (CRC), associations between fatty acids (FAs) and CRC have been inconsistent. Using Mendelian randomisation (MR), we sought to evaluate associations between polyunsaturated (PUFA), monounsaturated (MUFA) and saturated FAs (SFAs) and CRC risk.

Methods: We analysed genotype data on 9254 CRC cases and 18,386 controls of European ancestry. Externally weighted polygenic risk scores were generated and used to evaluate associations with CRC per one standard deviation increase in genetically defined plasma FA levels.

Results: Risk reduction was observed for oleic and palmitoleic MUFAs (OR OA = 0.77, 95% CI: 0.65–0.92, P = 3.9 × 10⁻³; OR POA = 0.36, 95% CI: 0.15–0.84, P = 0.018). PUFAs linoleic and arachidonic acid had negative and positive associations with CRC respectively (OR LA = 0.95, 95% CI: 0.93–0.98, P = 3.7 × 10⁻¹⁰⁻³; OR AA = 1.05, 95% CI: 1.02–1.07, P = 1.7 × 10⁻⁴). The SFA stearic acid was associated with increased CRC risk (OR SA = 1.17, 95% CI: 1.01–1.35, P = 0.041).

Conclusion: Results from our analysis are broadly consistent with a pro-inflammatory FA profile having a detrimental effect in terms of CRC risk.

© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Colorectal cancer (CRC) is one of the most common cancers and a major cause of cancer-related mortality in economically developed countries [1]. Geographical differences in CRC incidence between countries and migration studies have established the importance of lifestyle and diet as major determinants for CRC risk [2]. Worldwide CRC is currently diagnosed in over one million individuals annually; however, its incidence is set to increase with adoption of western lifestyles in developing countries [3]. Given the importance of diet as a risk factor for CRC, its modification offers the prospect of impacting significantly on disease incidence through public health initiatives.

Dietary fat has been widely implicated as a risk factor for cancer, and meta-analyses of epidemiological studies have tended to associate CRC risk with a higher consumption of red and processed meat [4]. The association between fat intake on cancer risk however, is likely to depend not only on the quantity, but also on the specific type of fatty acid (FA). Animal models and ecological studies have tended to implicate animal fat [5], saturated fatty acid (SFA) and certain omega-6 polyunsaturated fatty acids (ω-6 PUFAs) with an increased risk, and ω-3 PUFA intake with a reduced risk [6–8]. Evidence for a causal relationship with intake of specific types of fat from epidemiological studies has however largely been inconclusive. Reasons for inconsistencies in observational studies include the inherent problem of eliciting accurate measurements of long-term diet, confounding and reverse causation [9].

Mendelian randomisation (MR) analysis represents an adjunct to the conventional epidemiological observational study for examining associations between an exposure with a disease. The MR strategy makes use of allelic variants that are randomly assigned during meiosis and are robustly associated with traits of interest, as instrumental variables (IVs). Using genetically defined IVs as proxies of modifiable exposure avoids confounding by environmental factors, is not subject to reverse causality and can inform on life-long exposure [10,11]. Since studies have shown that FA intake influences plasma levels of FAs in theory MR makes an attractive strategy to link dietary FA to CRC risk [12,13].

We have therefore sought to identify associations between genetically predicted plasma PUFA, MUFAs and SFA levels and CRC risk. Specifically: (1) the ω-6 PUFAs, linoleic acid (LA), arachidonic acid (AA) and dihomo-γ-linolenic acid (DGLA); (2) the ω-3 PUFAs, eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA); (3) the MUFAs, oleic acid (OA) and palmitoleic acid (POA); and (4) the SFAs, palmitic acid (PA), arachidic acid and stearic acid (SA).

2. Methods

2.1. Colorectal cancer datasets

We investigated the relationship between genetic risk scores for levels of MUFAs, PUFAs, and SFAs and CRC risk adopting a two-sample MR strategy using data from seven reported genome-wide association studies (GWAS) of CRC (Table 1). Briefly, these GWAS were based on individuals with European ancestry: CCFR1, CCFR2, COIN, FINLAND, UK1, Scotland1 and VQ58 [14]. Each study was approved by respective institutional ethics review board and performed/conducted in accordance with the Declaration of Helsinki.

2.2. Genotyping data

Comprehensive details of the genotyping and quality control of the seven GWAS have been previously reported [14]. Briefly, we excluded single nucleotide polymorphisms (SNPs) with a minor allele frequency of <1%, low call rate <95%, those SNPs violating Hardy–Weinberg equilibrium, and individuals with non-European ancestry as assessed using data from HapMap v2 [15]. IMPUTEv2 software [16] was used to recover untyped SNP genotypes using a merged reference panel consisting of Sequencing Initiative Suomi (for the FINLAND data) or UK10K (for the remaining data) and 1000 Genomes Project data [17,18]. Poorly imputed SNPs, defined by an INFO score of <0.9, were excluded. Summary statistics from the seven GWAS were used to calculate the odds ratios (ORs) for FA-related SNPs.

2.3. Gene variants used to construct genetic risk scores

Genetic risk scores for IVs for each plasma FA were developed from SNPs previously identified by The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. We considered SNPs associated at genome-wide significance (i.e. \( P \leq 5.0 \times 10^{-8} \)) in individuals with European Ancestry. To avoid co-linearity between SNPs for each FA we imposed a threshold \( r^2 \) value of ≥0.01 for linkage disequilibrium (LD) including only the SNPs with the strongest effect on the trait in genetic risk scores (Table 2, [19–22]). For each identified SNP, we recovered the chromosome positions, the risk alleles, association estimates and standard errors. For each SNP, the allele that was associated with increased FA level was considered the effect allele.

2.4. Statistical analysis

The association between the plasma level of each FA and CRC was examined using MR on summary
Table 1
Summary of the seven colorectal cancer genome-wide association studies.

| Series     | Study setting                                | Study centre                      | Genotyping platform           | No. cases | No. controls |
|------------|----------------------------------------------|-----------------------------------|-------------------------------|-----------|-------------|
| CCFR1      | Colon Cancer Family Registry                 | University of Southern California | Illumina 1M, 1M Duo           | 1290      | 1055        |
| CCFR2      | Colon Cancer Family Registry                 | University of Southern California | Illumina 1M, Omni express     | 796       | 2236        |
| COIN       | COIN trial: Multicentre study of cetuximab and other therapies in metastatic CRC. Controls were unselected blood donors | Cardiff University                | Affymetrix Axiom             | 2244      | 2162        |
| FINLAND    | Finnish Colorectal Cancer Predisposition Study | Helsinki University              | Illumina 610K/Illumina HumanOmn2.5M | 1172      | 8266        |
| UK1        | CORG1 (colorectal Tumour Gene Identification Consortium) | Oxford University               | Illumina Hap550               | 940       | 965         |
| ScotlandI  | COGS (Colorectal Cancer Susceptibility Study) | Edinburgh University            | Illumina Hap300/240S          | 1012      | 1012        |
| VQ58       | Cases: VICTOR, post-treatment stages of a phase III, randomised trial of rofecoxib (VIOXX) in patients after potentially curative therapy. QUASAR2, multi-centre study of capecitabine ± bevacizumab as adjuvant treatment. 1958 Birth cohort controls | Oxford University               | Illumina Hap300/370, Illumina 1M | 1800      | 2690        |

Table 2
Effect sizes for plasma fatty acid content (per standard deviation increase in levels) for genome-wide significant ($P < 5 \times 10^{-8}$) instrumental variables reported by CHARGE consortium.

| FA subtype | Fatty acid     | SNP ID  | Chr | Position (bp) | Allele | β     | StdErr | $P$-value | Variance explained |
|------------|----------------|---------|-----|---------------|--------|-------|--------|-----------|-------------------|
| SFA        | Arachidonic acid (20:3) | rs680379 | 20  | 12917400 | A/G    | 0.098 | 0.01   | $5.81 \times 10^{-13}$ | -                 |
|            | Palmitic acid (PA) (16:0) | rs2391388 | 1   | 95485825 | C/A    | 0.18  | 0.03   | $2.72 \times 10^{-11}$ | 0.21–0.98%        |
|            | Stearic acid (SA) (18:0) | rs6675668 | 1   | 95515637 | G/T    | 0.17  | 0.02   | $2.16 \times 10^{-18}$ | 0.37–1.39%        |
| ω-3 PUFA   | Docosahexaenoic acid (DHA) (22:6n-3) | rs2236212 | 6   | 10995915 | G/C    | 0.11  | 0.01   | $1.26 \times 10^{-15}$ | 0.7%              |
|            | Docosapentaenoic acid (DPA) (22:5n-3) | rs780094 | 2   | 27741237 | T/C    | 0.02  | 0.003  | $9.04 \times 10^{-9}$  | -                 |
|            | Eicosapentaenoic acid (EPA) (20:5n-3) | rs3798713 | 6   | 11008622 | C/G    | 0.035 | 0.005  | $1.93 \times 10^{-12}$ | 0.4%              |
| ω-6 PUFA   | Arachidonic acid (AA) (20:4n-6) | rs174547 | 11  | 61570783 | T/C    | 1.69  | 0.03   | $3.30 \times 10^{-97}$ | 3.7–37.6%         |
|            | Dihomo-γ-linolenic acid (DGLA) (20:3n-6) | rs174547 | 11  | 61570783 | C/T    | 0.36  | 0.01   | $2.63 \times 10^{-15}$ | 8.7–11.1%         |
|            | Linoleic acid (LA) (18:2n-6) | rs10740118 | 10  | 65101207 | G/C    | 0.25  | 0.04   | $8.08 \times 10^{-9}$  | 0.2–0.7%          |
| ω-7 MUFA   | Palmitoleic acid (POA) (16:1n-7) | rs780093 | 2   | 27742603 | T/C    | 0.02  | 0.003  | $9.80 \times 10^{-10}$ | 0.23–0.93%        |
|            | Oleic acid (OA) (18:1n-9) | rs102275 | 11  | 61557803 | C/T    | 0.23  | 0.02   | $2.19 \times 10^{-32}$ | 0.32–2.14%        |

FA, fatty acid; SNP, single nucleotide polymorphism; bp, base pair; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; StdErr, standard error. Effect allele influencing each FA trait is marked in bold.

a hg19 NCBI build.

b Taken from CHARGE consortium, as a percentage of total serum fatty acids, calculated by $(\beta^2+2\times MAF*(1-MAF))/Var(Y)$ where β is the regression coefficient, MAF is the minor allele frequency and Var(Y) is the variance in levels of the fatty acid. IVs obtained from Refs. [19,20,22].
2.5. Expression quantitative trait locus analysis

To examine the relationship between SNP genotype and expression of FA metabolism genes, we performed expression quantitative trait locus (eQTL) analysis using data from The Cancer Genome Atlas (TCGA) and the genotype tissue expression (GTEx) project [26,27].

3. Results

The FA-associated genetic variants and their GWAS-reported characteristics that were used to derive IVs for FAs are detailed in Table 2. A reduced risk of CRC was observed for genetic variants associated with increases in the MUFAs studied (Table 3). In all but one of the seven cohorts increased levels of OA were associated with reduced CRC risk (Fig. 1). In the meta-analysis of these seven cohorts the OROA was 0.77 (95% CI: 0.65–0.92, \( P = 3.9 \times 10^{-3}\)) with little evidence of between-study heterogeneity (\( P_{\text{het}} = 0.23, \hat{I}^2 = 26\%\)). Similarly, increased levels of POA were associated with reduced CRC risk with an ORPOA of 0.36 (95% CI: 0.15–0.84, \( P = 0.018, P_{\text{het}} = 0.08, \hat{I}^2 = 47\%\), Fig. 1).

The \( \omega-6 \) PUFAs LA and AA both showed association with CRC risk, but in different directions. Specifically, LA was associated with reduced risk (ORLA = 0.95, 95% CI: 0.93–0.98, \( P = 3.7 \times 10^{-4}\), \( P_{\text{het}} = 0.03, \hat{I}^2 = 57\%\); Fig. 1) and AA with an increased risk (ORAA = 1.05, 95% CI: 1.02–1.07, \( P = 1.7 \times 10^{-4}\), \( P_{\text{het}} = 0.03, \hat{I}^2 = 56\%\)). The association between one standard deviation increase in each of the other PUFAs defined by their respective IVs and CRC risk were null (Supplementary Fig. 1).

Of the three SFAs studied, increased SA was nominally associated with CRC risk (ORSA = 1.17, 95% CI: 1.01–1.35, \( P = 0.041, P_{\text{het}} = 0.04, \hat{I}^2 = 55\%\)).

To formally assess the impact of heterogeneity on study findings we derived ORs under a random-effects model.
model. Associations between AA, LA and OA and CRC risk remained significant (Table 3).

We assessed the impact of possible classical pleiotropism on MR estimates using both IVW and MR-Egger regression tests. There was no evidence for violation of the standard IV assumptions used for MR analysis, such as a dependence on confounders (Table 4).

In the present analysis, we used the SNP rs102275 in combination with other SNPs to generate a polygenic risk score for SA, OA and POA, whereas rs174547, which is in LD with rs102275 ($r^2 = 1.0$ and $D' = 1.0$), was used for DPA, AA, DGLA and LA. Both SNPs annotate the FADS2 gene. FADS2 is a rate-limiting enzyme in the desaturation of LA to AA, and α-linolenic acid into DHA and EPA (Fig. 2). These FAs are precursors for prostaglandins and leukotrienes, which are key mediators of the inflammatory response. In an eQTL analysis rs174547 and rs102275 genotype were shown to be strongly correlated with FADS2 expression across a range of different tissue types, including blood ($P = 3.98 \times 10^{-20}$), normal colon ($P = 1.65 \times 10^{-10}$) and CRC ($P = 2.07 \times 10^{-5}$) (Supplementary Table 1).

---

### Table 3: Associations between AA, LA and OA and CRC risk

| Study     | Oleic acid OR (95% CI) | Arachidonic acid OR (95% CI) | Stearic acid OR (95% CI) | Linoleic acid OR (95% CI) | Palmitoleic acid OR (95% CI) |
|-----------|------------------------|-------------------------------|--------------------------|---------------------------|-------------------------------|
| UK1       | 0.63 [0.34; 1.16]      | 1.07 [0.98; 1.16]             | 1.12 [0.68; 1.85]        | 0.94 [0.86; 1.04]         | 0.30 [0.02; 5.31]              |
| Scotland1 | 0.68 [0.38; 1.22]      | 1.15 [1.06; 1.25]             | 1.18 [0.73; 1.90]        | 0.86 [0.78; 0.94]         | 0.25 [0.02; 4.10]              |
| VQ58      | 0.81 [0.56; 1.19]      | 1.03 [0.98; 1.08]             | 1.08 [0.79; 1.49]        | 0.97 [0.92; 1.03]         | 0.47 [0.07; 3.01]              |
| CCFR1     | 0.66 [0.38; 1.12]      | 1.06 [0.98; 1.14]             | 1.31 [0.84; 2.07]        | 0.96 [0.88; 1.03]         | 0.12 [0.01; 1.51]              |
| CCFR2     | 0.50 [0.30; 0.85]      | 1.11 [1.03; 1.19]             | 2.03 [1.31; 3.14]        | 0.89 [0.82; 0.96]         | 0.20 [0.02; 2.41]              |
| COIN      | 1.20 [0.80; 1.79]      | 0.98 [0.93; 1.03]             | 0.77 [0.55; 1.07]        | 1.03 [0.97; 1.09]         | 4.47 [0.67; 29.85]             |
| FIN       | 0.78 [0.52; 1.21]      | 1.05 [0.99; 1.10]             | 1.34 [0.95; 1.88]        | 0.95 [0.91; 1.00]         | 0.05 [0.01; 0.39]              |

### Table 4: Standard IV assumptions for MR analysis

| Study     | Violation of IV assumptions | Heterogeneity: $I^2$%
|-----------|-----------------------------|-------------------------|
| UK1       | No violation                | 26%                     |
| Scotland1 | No violation                | 55%                     |
| VQ58      | No violation                | 55%                     |
| CCFR1     | No violation                | 57%                     |
| COIN      | No violation                | 47%                     |

---

**Fig. 1.** Meta-analysis odds ratios (OR) for colorectal cancer per unit increase in genetic risk score (standard deviation of trait) for significant fatty acid associations. (a) Oleic acid; (b) arachidonic acid; (c) stearic acid; (d) linoleic acid; (e) palmitoleic acid. $I^2$: proportion of the total variation due to heterogeneity. Boxes: OR point estimate; its area is proportional to the weight of the study. Diamond: overall summary estimate, with confidence intervals given by its width. Vertical line: null value (OR = 1.0).
Table 4
IVW and MR-Egger test results for combined fatty acid instrumental variables.

| Fatty acid subtype | Fatty acid                        | IVW Slope Estimate (95% CI) | IVW P-value | MR-Egger Estimate (95% CI) | MR-Egger P-value |
|--------------------|----------------------------------|----------------------------|-------------|-----------------------------|------------------|
| SFA                | Stearic acid (SA)                | −0.1 (−0.33 to 0.64)       | 0.30        | Intercept −0.68 (−4.79 to 3.43) | 0.28             |
|                    |                                  |                            |             | Slope 4.10 (−19.86 to 28.06) | 0.27             |
| ω-3 PUFA           | Docosapentaenoic acid (DPA)      | 0.46 (−2.32 to 3.23)       | 0.55        | Intercept −0.09 (−0.56 to 0.39) | 0.26             |
|                    |                                  |                            |             | Slope 2.01 (−7.9 to 11.61)   | 0.23             |
| ω-6 PUFA           | Arachidonic acid (AA)            | −0.59 (−7.99 to 9.16)      | 0.54        | Intercept −0.11 (N/A)        | −                |
|                    |                                  | −0.09 (−2.48 to 2.29)      | 0.70        | Intercept 0.04 (N/A)         | −                |
|                    | Dihomo-γ-linolenic acid (DGLA)   | −0.05 (−0.17 to 0.07)      | 0.22        | Intercept −0.25 (N/A)        | −                |
|                    | Limoleic acid (LA)               | −0.10 (−0.04 to 0.07)      | 0.90        | Intercept −0.90 (N/A)        | −                |
| MUFA               | Palmitoleic acid (POA)           | −1.03 (−2.64 to 0.58)      | 0.15        | Intercept −0.07 (−0.81 to 0.68) | 0.46             |
                      |                                  |                            |             | Slope −0.07 (−0.81 to 0.68)  | 0.46             |
                      |                                  |                            |             | Intercept −0.11 (−0.27 to 0.05) | 0.12             |
                      |                                  |                            |             | Slope 3.13 (−3.16 to 9.41)   | 0.21             |

CI, confidence interval; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; IVW, inverse variant weighted. *FA traits with two IVs, preventing calculation of CIs and P-value.

4. Discussion

While dietary fat intake has been associated with the CRC risk, teasing out specific FA associations and their mechanistic basis has proven to be challenging. A number of observational studies have reported associations between serum levels of specific FAs with CRC [28,29], supporting our findings.

A major strength of the MR strategy to identify causal associations is that it is not influenced by recall bias and confounding that can affect traditional observational studies. Nevertheless, a key assumption in MR is that the variants used to generate genetic scores are associated with the exposure being queried. Herein, we only made use of SNPs associated with each FA at genome-wide significance from hypothesis-free GWAS. Furthermore, we only used data from individuals of European descent so as to limit bias from population stratification. Another central assumption in MR is that variants are associated with CRC only through the exposure and are not confounded by pleiotropy, which would be revealed by a positive correlation between increasing effect sizes in the IVs and CRC risk. While we did not observe such relationship, we acknowledge that IVs for a number of the FAs were solely based on only one or two SNPs, preventing assessment by IVW and MR-Egger analysis. One strategy to overcome this and fully investigate any pleiotropy would be to measure FA serum levels in correlation with CRC risk.

In this analysis, the same SNP (rs102275, or correlated SNP rs174547) was used to make causal deductions between multiple FAs and CRC risk. Therefore, SNPs have been used each time assuming that the exposure individually accounts for the disease association. The genetic variant association with CRC risk is consequently double-counted, in that the effect is attributed to different FA exposures [30]. With such vertical pleiotropism, single locus MR analyses cannot robustly decipher which FA is primarily driving the relationship with CRC risk. Such considerations have not been addressed in previous studies of the relationship between PUFAs and prostate cancer [31] or between branched-chain amino acids and diabetes [32].

While we did not demonstrate a causal association between other FAs including several PUFAs, SFAs and CRC risk, we acknowledge that our power to demonstrate a relationship was limited. For example, with respect to EPA: assuming the variance explained by the alleles is 0.04%, based on epidemiological observational study data, and a relative risk of 1.04 we had <10% power to demonstrate a relationship [33].

Accepting these caveats we have provided support for differing effects of OA, and ω-6 PUFAs LA and AA on CRC risk. Our findings broadly accord with the findings from many of the published ecological and epidemiological observational studies. Notably, increased levels of AA contribute as a risk factor to CRC development [34,35], while increased intake of olive oil, which is high in OA, is associated with decreased risk [36]. A number of epidemiological studies have provided evidence that a Mediterranean diet, with a higher olive oil intake, is associated with reduced CRC risk [36–38].

In the eQTL analysis, both rs102275 and rs174547 show evidence of cis-regulatory effects on FADS2 expression. Intriguingly, rs174547 has previously been reported to have opposing effects on FADS2 and FADS1 expression in CRC [39]. Collectively, these data provide for relationship between diet, genotype, FA metabolism and CRC risk through modulation of an inflammatory response.

Even so, a biological basis for associations between specific FAs and CRC risk remain to be established. It is however, predicted a priori that within any FA class, different members have different actions and effects. With
respects to $\omega-6$, evidence supports the inflammatory effects for AA through COX-2 production of inflammatory mediators [40] including prostaglandin E2, which affect CRC carcinogenesis [41–43]. This implies that diets high in AA, such as meat or eggs, may lead to more inflammatory compounds, which in turn may increase CRC risk. While increasing dietary LA, an essential FA, might potentially enrich tissues with AA due to their metabolic link [44], a gene—environment interaction may exist to influence colon FA content [45]. There is however, contradictory evidence from studies that have associated LA with both an increased [46] and decreased risk of CRC, possibly by altering $\omega-6$ to $\omega-3$ FA ratios [47] or alternatively production of reactive oxygen species [48]. The ability of aspirin to irreversibly inhibit COX-1 and COX-2 and therefore lower pro-inflammatory signals independent of genotype and diet, has thus proved an attractive option for CRC chemoprevention [49].

Fig. 2. Pathway of fatty acids. Shown are the various fatty acids analysed, and the enzymes involved in their metabolism. COX: cyclooxygenase, LOX: 5-lipoxygenase.
In conclusion, irrespective of the biological basis of associations between FAs and CRC risk our findings are consistent with the observation that the dietary composition of MUFAs in Mediterranean diets are risk reducing, and that a pro-inflammatory diet are risk increasing [50]. While we may not be at a stage where we can justifiably advise individuals to alter their intake of specific FAs to decrease the risk of developing CRC, it seems the current guidelines to moderate total fat and SFA consumption and increase unsaturated FA intake is likely to be beneficial.

Conflict of interest statement

None declared.

Acknowledgements

At the Institute of Cancer Research, this work was supported by Cancer Research UK (C1298/A8362 - Bobby Moore Fund for Cancer Research UK). Additional support was provided by the National Cancer Research Network. S. M-W was in receipt of a PhD studentship from The Institute of Cancer Research. A.S. is supported by a clinical fellowship from Cancer Research UK. In Edinburgh the work was supported by Programme Grant funding from Cancer Research UK (C348/A12076). In Oxford additional funding was provided by the Oxford Comprehensive Biomedical Research Centre and the EU FP7 CHIBCHA grant. Core infrastructure support to the Wellcome Trust Centre for Human Genetics, Oxford was provided by grant (090532/Z/09/Z). We are grateful to many colleagues within UK Clinical Genetics Departments (for CORGI) and to many collaborators who participated in the VICTOR and QUASAR2 trials. We also thank colleagues from the UK National Cancer Research Network (for NSCCG). Support from the European Union (FP7/207-2013, grant 258236) and FP7 collaborative project SYSCOL and COST Action in the UK is also acknowledged (BM1206). The COIN and COIN-B trials were funded by Cancer Research UK and the Medical Research Council and were conducted with the support of the National Institute of Health Research Cancer Research Network. COIN and COIN-B translational studies were supported by the Bobby Moore Fund from Cancer Research UK, Tenovus, the Kidani Trust, Cancer Research Wales and the National Institute for Social Care and Health Research Cancer Genetics Biomedical Research Unit (2011–2014). N.A.A., B.F.M. and S.M.W. were funded and supported by KFSHR. In Finland, this work was supported by grants from the Academy of Finland (Finnish Center of Excellence Program 2012–2017, 250345), the Jane and Aatos Erkko Foundation, the Finnish Cancer Society (K.P.), the European Research Council [ERC; 268648], the Sigrid Juselius Foundation, SYSCOL, the Nordic Information for Action eScience Center (NIASC), the Nordic Center of Excellence financed by NordForsk (project 62721, K.P.) and State Research Funding of Kuopio University Hospital (B1401). We acknowledge the computational resources provided by the ELIXIR node, hosted at the CSC–IT Center for Science, Finland, and funded by the Academy of Finland (grants 271642 and 263164), the Ministry of Education and Culture, Finland. V.S. was supported by the Finnish Academy (grant number 139635). Sample collection and genotyping in the Finnish Twin Cohort has been supported by the Wellcome Trust Sanger Institute, ENGAGE — European Network for Genetic and Genomic Epidemiology, FP7-HEALTH-F4-2007 (201413), the National Institute of Alcohol Abuse and Alcoholism [grants AA-12502 and AA-00145 to Richard J Rose and K02AA018755 to Danielle M Dick] and the Academy of Finland (100499, 205585, 265240 and 263278 to J.K.). The work of the Colon Cancer Family Registry (CCFR) was supported by from the National Cancer Institute (UMI CA167551), National Institutes of Health and through cooperative agreements with the following CCFR centers: Australasian Colorectal Cancer Family Registry (U01 CA074778, U01/U24 CA097735), USC Consortium Colorectal Cancer Family Registry (U01/U24 CA074799), Mayo Clinic Cooperative Familial Registry for Colon Cancer Studies (U01/U24 CA074800), Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783), Seattle Colorectal Cancer Family Registry (U01/U24 CA074794), and University of Hawaii Colorectal Cancer Family Registry (U01/U24 CA074806). The CCFR Illumina GWAS was supported by funding from the National Cancer Institute, National Institutes of Health (U01 CA122839 and R01 CA143237 to G.C.). Additional support was provided from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute to Fred Hutchinson Cancer Research Center (Control Nos. N01-CN-67009, N01-PC-35142 and Contract No. HHSN2612013000121), the Hawai'i Department of Health (Control Nos. N01-PC-67001, N01-PC-35137, and Contract No. HHSN26120100037C), and the California Department of Public Health (contract HHSN26120100035C) awarded to the University of Southern California. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute, any SEER program or any of the collaborating centres in the CCFR, nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government, SEER or the CCFR.

We are grateful to all individuals who participated in the various studies. This study made use of genotyping data from the 1958 Birth Cohort, kindly made available by the Wellcome Trust Case Control Consortium 2. A full list of the investigators who contributed to the
Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.ejca.2017.07.034.

References

[1] Forman D, Brewster DH, Kohler B, Pineros M. Cancer incidence in five continents Vol. X (164). IARC Sci Publ 2014;164(Pt 1):23–36.

[2] Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24(14):2137–50.

[3] Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009;22(4):191–7.

[4] Aykan NF. Red meat and colorectal cancer. Oncol Rev 2015;9(1):288.

[5] Reddy BS. Types and amount of dietary fat and colon cancer risk: prevention by omega-3 fatty acid-rich diets. Environ Health Prev Med 2002;7(3):95–102.

[6] Bartsch H, Nair J, Owen RW. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. Carcinogenesis 1999;20(12):2199–208.

[7] Roynette CE, Calder PC, Dupertuis YM, Pichard C. n-3 polyunsaturated fatty acids and colon cancer prevention. Clin Nutr 2004;23(2):139–51.

[8] Azrad M, Turgeon C, Demark-Wahnefried W. Current evidence linking polyunsaturated Fatty acids with cancer risk and progression. Front Oncol 2013;3:224.

[9] Thedodoratou E, McNeill G, Cetnarskyj R, Farrington SM, Tenesa A, Barnetson R, et al. Dietary fatty acids and colorectal cancer: a case-control study. Am J Epidemiol 2007;166(2):181–95.

[10] Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014;23(R1):R89–98.

[11] Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32(1):1–22.

[12] Hagfors L, Nilsson I, Skoldstam L, Johansson G. Fat intake and colon cancer in patients with rheumatoid arthritis. Nutr Metab (Lond) 2005;2:26.

[13] Ranković S, Popović T, Martić JD, Petrović S, Tomić M, Ignjatović D, et al. Liver phospholipids fatty acids composition in response to different types of diets in rats of both sexes. Lipids Health Dis 2017;16:94.

[14] Orlando G, Law PJ, Palin K, Tuupanen S, Gyfle A, Hanninen UA, et al. Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease. Hum Mol Genet 2016;25(11):2349–59.

[15] International HapMap C, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449(7164):851–61.

[16] Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009;5(6), e1000529.

[17] Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature 2015;526(7571):68–74.

[18] Consortium UK, Walter K, Min JL, Huang J, Crooks L, Memari Y, et al. The UK10K project identifies rare variants in health and disease. Nature 2015;526(7571):82–90.

[19] Wu JH, Lemaître RN, Manichaikul A, Guan W, Tanaka T, Foy M, et al. Genome-wide association study identifies novel loci associated with concentrations of four plasma phospholipid fatty acids in the de novo lipogenesis pathway: results from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2013;6(2):171–83.

[20] Guan W, Steffen BT, Lemaître RN, Wu JH, Tanaka T, Manichaikul A, et al. Genome-wide association study of plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research in genomic epidemiology consortium. Circ Cardiovasc Genet 2014;7(3):321–31.

[21] Lemaître RN, King IB, Kabagambe EK, Wu JH, McKeight B, Manichaikul A, et al. Genetic loci associated with circulating levels of very long-chain saturated fatty acids. J Lipid Res 2015;56(1):176–84.

[22] Lemaître RN, Tanaka T, Wang W, Manichaikul A, Foy M, Kabagambe EK, et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet 2011;7(7), e1002193.

[23] Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Consortium E-I. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol 2015;30(7):543–52.

[24] Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44(2):512–25.

[25] R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2015. 3.1 ed.

[26] Aguet F, Brown AA, Castel S, Davis JR, Mohammadi P, Segre AV, et al. Local genetic effects on gene expression across 44 human tissues. bioRxiv 2016. http://dx.doi.org/10.1101/074505.

[27] Consortium GT, The genotypic-tissue expression (GTEX) project. Nat Genet 2013;45(6):580–5.

[28] Kondo Y, Nishiumi S, Shihohara M, Hatano N, Ikeda A, Yoshie T, et al. Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomark Med 2011;5(4):451–60.

[29] Zhang P, Wen X, Gu F, Zhang X, Li J, Liu Y, et al. Role of serum polyunsaturated fatty acids in the development of colorectal cancer. Int J Clin Exp Med 2015;8(9):15900–9.

[30] Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol 2017. http://dx.doi.org/10.1038/nrcardio2017.78.

[31] Khankari NK, Murff HJ, Zeng C, Wen W, Eeles RA, Easton DF, et al. Polymethylated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. Br J Cancer 2016;115(5):624–31.

[32] Lotta LA, Scott RA, Sharp SJ, Burgess S, Luan J, Tillin T, et al. Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a Mendelian randomization analysis. PLoS Med 2016;13(11), e1002179.

[33] Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 2013;42(5):1497–501.

[34] Murff HJ, Xu XO, Li H, Dai Q, Kallianpur A, Yang G, et al. A prospective study of dietary polyunsaturated fatty acids and colorectal cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2009;18(8):2283–91.

[35] Nkondjock A, Shatenstein B, Maisonneuve P, Ghadirian P. Assessment of risk associated with specific fatty acids and health and disease. Nature 2015;526(7571):82–90.
colorectal cancer among French-Canadians in Montreal: a case-control study. Int J Epidemiol 2003;32(2):200–9.

[36] Psaltopoulou T, Kosti RI, Haidopoulos D, Dimopoulos M, Panagiotakos DB. Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of 13,800 patients and 23,340 controls in 19 observational studies. Lipids Health Dis 2011;10:127.

[37] Filik L, Ozyilkan O. Olive-oil consumption and cancer risk. Eur J Clin Nutr 2003;57(1):191.

[38] Llor X, Pons E, Roca A, Alvarez M, Mane J, Fernandez-Banares F, et al. The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin Nutr 2003;22(1):71–9.

[39] Loo LWM, Lemire M, Le Marchand L. In silico pathway analysis and tissue specific cis-eQTL for colorectal cancer GWAS risk variants. BMC Genomics 2017;18(1):381.

[40] Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011;31(5):986–1000.

[41] Wang D, DuBois RN. An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J 2013;19(6):502–10.

[42] Wang D, Fu L, Sun H, Guo L, DuBois RN. Prostaglandin E2 promotes colorectal cancer stem cell expansion and Metastasis in Mice. Gastroenterology 2015;149(7):1884–1895 e4.

[43] Monjazeb AM, High KP, Connoy A, Hart LS, Koumenis C, Chilton FH. Arachidonic acid-induced gene expression in colon cancer cells. Carcinogenesis 2006;27(10):1950–60.

[44] Mohrhauer H, Holman RT. The effect of dose level of essential fatty acids upon fatty acid composition of the Rat liver. J Lipid Res 1963;4:151–9.

[45] Porenta SR, Ko YA, Gruber SB, Mukherjee B, Baylin A, Ren J, et al. Interaction of fatty acid genotype and diet on changes in colonic fatty acids in a Mediterranean diet intervention study. Cancer Prev Res (Phila) 2013;6(11):1212–21.

[46] Zock PL, Katan MB. Linoleic acid intake and cancer risk: a review and meta-analysis. Am J Clin Nutr 1998;68(1):142–53.

[47] Lu XF, He GQ, Yu HN, Ma Q, Shen SR, Das UN. Colorectal cancer cell growth inhibition by linoleic acid is related to fatty acid composition changes. J Zhejiang Univ Sci B 2010;11(12):923–30.

[48] Lu X, Yu H, Ma Q, Shen S, Das UN. Linoleic acid suppresses colorectal cancer cell growth by inducing oxidant stress and mitochondrial dysfunction. Lipids Health Dis 2010;9:106.

[49] Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016;16(3):173–86.

[50] Shivappa N, Steck SE, Hurley TG, Hussey JR, Hebert JR. Designing and developing a literature-derived, population-based dietary inflammatory index. Public Health Nutr 2014;17(8):1689–96.